
Insilico Medicine Launches Phase III Trial for AI-Designed IPF Drug
Insilico Medicine has initiated a Phase III clinical trial for Rentosertib, a first-in-class oral inhibitor targeting TNIK to treat idiopathic pulmonary fibrosis. This marks a milestone for the company, as the drug—discovered and optimized entirely through generative AI—advances into late-stage testing to address a severe, progressive lung disease.

























